Hmmm. I am noticing that ex-US trials are not reporting race... Should this be a required element for @ASCO presentations? 
Study design of MITO-23
MITO23 endpoints:
Primary: Overall Survival
Secondary: Progression Free Survival
Very interesting that OS was the primary endpoint I think...
Primary: Overall Survival
Secondary: Progression Free Survival
Very interesting that OS was the primary endpoint I think...
Nice CONSORT diagram showing who was included in what analysis:
Hmmm. I am noticing that ex-US trials are not reporting race... Should this be a required element for @ASCO presentations for #ASCO23 and beyond?
Prof. Lorusso: Trabectidin failed to demonstrate an increase in overall survial (same in progression free survival).
Finally, the appropriate way to use "fail" in the context of trial reporting.
Finally, the appropriate way to use "fail" in the context of trial reporting.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
